A Clinical Trial to Study the Effect of a Drug, Curcumin in Patients With Periodontitis
Evaluation of the Host Modulating Effects of 1% Curcumin Chips as an Adjunct to Non Surgical Mechanical Debridement in the Treatment of Periodontitis: A Randomised Controlled Clinical Trial
1 other identifier
interventional
40
1 country
1
Brief Summary
The study will follow a parallel arm, randomised, double blinded, placebo controlled design. There will be two groups Group 1 = receiving 1% curcumin chips after routine scaling and root planing (n=20) Group 2 = receiving placebo chips after routine scaling and root planing (n=20) Clinical parameters: ( Baseline, 4 weeks, 12 weeks) Probing pocket depth, clinical attachment level, gingival index, plaque index Cytokine parameter ( Baseline, 4 weeks) Interleukin 1 beta in GCF Statistical analysis Repeated measures of ANOVA Paired t-tests
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Sep 2019
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 19, 2018
CompletedFirst Posted
Study publicly available on registry
December 31, 2018
CompletedStudy Start
First participant enrolled
September 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedDecember 13, 2019
December 1, 2019
12 months
December 19, 2018
December 12, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cytokine parameter
Intragroup comparison within each group (1-curcumin group and 2- placebo group) and intergroup comparison between the two groups of levels of interleukin 1 beta in the gingival crevicular fluid quantified by ELISA in picogram per milliliter
Change from Baseline to 4 weeks
Secondary Outcomes (4)
Probing pocket depth
Changes from Baseline to 4 weeks and 12 weeks
Clinical attachment level
Changes from Baseline to 4 weeks and 12 weeks
Gingival Bleeding Index by Loe and Silness in 1963
Changes from Baseline to 4 weeks and 12 weeks
Plaque index by Silness and Loe in 1964
Baseline from. 4 weeks, 12 weeks
Study Arms (2)
1% curcumin chip
EXPERIMENTALFollowing routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)
Placebo chip
PLACEBO COMPARATORFollowing routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)
Interventions
CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
Eligibility Criteria
You may qualify if:
- Systemically healthy individuals
- Presence of a minimum of 20 teeth in the oral cavity
- Localised periodontal pockets with probing depths greater than 4mm i.e., Periodontitis in its stages 2 and 3, as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and published by the American Academy of Periodontology (AAP)
You may not qualify if:
- Known allergy to curcumin and/ or hydroxyl propyl methyl cellulose
- Systemic diseases and/or Inflammatory conditions, Obesity
- Former or current tobacco users
- Chronic consumption of alcohol
- Use of anti-inflammatory drugs and antibiotics over the past 3 months
- Periodontal therapy in any form, surgical or non surgical in the past 6 months
- Pregnant and lactating mothers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
K L E society's Dental College
Bangalore, Karnataka, 560022, India
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- The study design follows a double blinded design where the participant and the outcome assessor are unaware of the intervention to the subject
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Post graduate student, Principal Investigator, Department of Periodontics, KLE Society's Institute of Dental Sciences, Bangalore
Study Record Dates
First Submitted
December 19, 2018
First Posted
December 31, 2018
Study Start
September 4, 2019
Primary Completion
September 1, 2020
Study Completion
December 1, 2020
Last Updated
December 13, 2019
Record last verified: 2019-12
Data Sharing
- IPD Sharing
- Will not share
For the purpose of confidentiality, as will be promised to the participants while signing the informed consent, all individual records except that of the parameters assessed during the study and the photographs taken will remain unshared to the public or fellow researchers